About Endometriosis
Endometriosis is a common female health condition where the endometrial tissue, which is usually found inside the lining of the uterus, appear and grows outside the uterine cavity. Endometriosis mostly occurs in the fallopian tubes, ovaries, outer surface of the uterus, pelvic cavity, vagina, cervix, and bladder. Endometriosis has rarely been reported in more distant parts of the body such as the lungs, brain, and skin. The most common symptoms associated with endometriosis are pelvic pain, dysmenorrhea, excessive bleeding, and lower abdominal pain. Some of the uncommon symptoms of endometriosis are rectal bleeding and hematuria. The detection of endometriosis in women is difficult because of the common symptoms associated with it. Endometriosis can be diagnosed by laparoscopy, ultrasound, pelvic exam, and biopsy of the inner lining of the uterus. In a biopsy, the tissues from the inner lining of the uterus of the patient are taken and tested using the biomarkers for the presence of endometriosis. Endometriosis is an incurable disease and relapses after the primary treatment. Currently, the treatment options for endometriosis include the usage of hormone therapy and analgesics to control the disease.
TechNavio's analysts forecast the Global Endometriosis market will grow at a CAGR of 2.86 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Endometriosis market for the period 2013-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of endometriosis that are available in the market.
TechNavio's report, the Global Endometriosis Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, EMEA, and APAC regions; it also covers the Global Endometriosis market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• EMEA
• APAC
Key Vendors
• Abbvie Inc.
• AstraZeneca plc
• Bayer AG
• Pfizer Inc.
Other Prominent Vendors
• Astellas Pharma Inc.
• Abbvie Inc.
• Repros Therapeutics Inc.
• Sanofi SA
• Takeda Pharmaceuticals Co. Ltd.
Key Market Driver
• High Unmet Needs in the Market
• For a full, detailed list, view our report.
Key Market Challenge
• Patent Expiries of Approved Drugs
• For a full, detailed list, view our report.
Key Market Trend
• Expected Launch of High-cost Therapies
• For a full, detailed list, view our report.
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
03.2.1 Product Profiles
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Rate of Incidence and Prevalence
08. Market Segmentation by Type of Therapy
08.1.1 Hormone Therapy
08.1.2 Analgesics
09. Market Segmentation by Route of Administration and Type of Dosage Form
09.1.1 Oral
09.1.2 Parenteral
09.1.3 Topical
10. Pipeline Portfolio
11. Geographical Segmentation
12. Buying Criteria
13. Market Growth Drivers
14. Drivers and their Impact
15. Market Challenges
16. Impact of Drivers and Challenges
17. Market Trends
18. Trends and their Impact
19. Vendor Landscape
19.1 Competitive Scenario
19.1.1 Key News
19.2 Market Share Analysis 2013
19.3 Other Vendors
20. Key Vendor Analysis
20.1 AbbVie Inc.
20.1.1 Key Facts
20.1.2 Business Description
20.1.3 Product Segmentation
20.1.4 Revenue by Product Line
20.1.5 Revenue Comparison 2012 and 2013
20.1.6 Revenue by Geographical Segmentation
20.1.7 Business Strategy
20.1.8 Key Developments
20.1.9 SWOT Analysis
20.1.10 Strengths
20.1.11 Weaknesses
20.1.12 Opportunities
20.1.13 Threats
20.2 AstraZeneca plc
20.2.1 Key Facts
20.2.2 Business Overview
20.2.3 Business Segmentation
20.2.4 Business Strategy
20.2.5 Revenue by Business Segmentation
20.2.6 Revenue Comparison 2011-2013
20.2.7 Sales by Geography
20.2.8 Key Developments
20.2.9 SWOT Analysis
20.2.10 Strengths
20.2.11 Weaknesses
20.2.12 Opportunities
20.2.13 Threats
20.3 Bayer AG
20.3.1 Key Facts
20.3.2 Business Overview
20.3.3 Business Segmentation
20.3.4 Business Strategy
20.3.5 Sales Segmentation by Business
20.3.6 Sales by Geographical Segmentation
20.3.7 Key Information
20.3.8 SWOT Analysis
20.3.9 Strengths
20.3.10 Weaknesses
20.3.11 Opportunities
20.3.12 Threats
20.4 Pfizer Inc.
20.4.1 Key Facts
20.4.2 Business Overview
20.4.3 Business Segmentation by Revenue 2013
20.4.4 Business Segmentation by Revenue 2012 and 2013
20.4.5 Sales by Geography
20.4.6 Business Strategy
20.4.7 Key Developments
20.4.8 SWOT Analysis
20.4.9 Strengths
20.4.10 Weaknesses
20.4.11 Opportunities
20.4.12 Threats
21. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Endometriosis Market 2013-2018 (US$ million)
Exhibit 3: Global Endometriosis Market by Type of Therapy
Exhibit 4: Global Endometriosis Market Segmentation by Type of Therapy 2013
Exhibit 5: Global Endometriosis Market by Route of Administration and Type of Dosage Form
Exhibit 6: Pipeline Portfolio of the Drugs for Endometriosis
Exhibit 7: Global Endometriosis Market by Geographical Segmentation 2013
Exhibit 8: AbbVie Inc.: Product Segmentation
Exhibit 9: AbbVie Inc.: Revenue by Product Line 2013
Exhibit 10: AbbVie Inc.: Revenue Comparison by Product Line 2012 and 2013 (US$ billion)
Exhibit 11: AbbVie Inc.: Revenue by Geographical Segmentation 2013
Exhibit 12: AstraZeneca plc: Business Segmentation
Exhibit 13: AstraZeneca plc: Business Segmentation by Revenue 2013
Exhibit 14: AstraZeneca plc: Business Segmentation by Revenue 2011-2013 (US$ billion)
Exhibit 15: AstraZeneca plc: Sales by Geography 2013
Exhibit 16: Business Segmentation of Bayer AG 2013
Exhibit 17: Sales Comparison of Bayer AG by Business Segment 2012 and 2013 (US$ million)
Exhibit 18: Sales Segmentation of Bayer AG by Geography 2013
Exhibit 19: Pfizer Inc.: Business Segmentation by Revenue 2013
Exhibit 20: Pfizer Inc.: Business Segmentation by Revenue 2012 and 2013
Exhibit 21: Pfizer Inc.: Sales by Geography 2013
